Advertisement

An outbreak of Clostridium difficile PCR ribotype 027 in Spain: risk factors for recurrence and a novel treatment strategy

  • E. BouzaEmail author
  • L. Alcalá
  • M. Marín
  • M. Valerio
  • E. Reigadas
  • P. Muñoz
  • M. González-Del Vecchio
  • V. de EgeaEmail author
Original Article

Abstract

An outbreak of Clostridium difficile infection (CDI) caused by ribotype 027 (B1/NAP1) began in our hospital in November 2014, and produced 141 episodes in the following months. The aim of this study is to describe this outbreak, assess risk factors for recurrence of CDI-027 and to analyze the implementation of a novel treatment strategy. This is a prospective study of all patients with CDI-027, from November 2014 to November 2015. The epidemiological data were collected daily for each patient. We compared clinical characteristics and treatment between patients with and without recurrence of CDI-027. Interestingly, liver cirrhosis was present in 22% of the patients, and most of them received prophylaxis for hepatic encephalopathy with rifaximin. Patients were also taking antimicrobial drugs (93.6%) and proton pump inhibitors (80.1%). Overall, 27 (23.5%) patients had a first recurrence of CDI-027. Liver cirrhosis increased the risk of recurrence (44.4% vs 14.8%). Patients treated with a prolonged oral vancomycin regimen vs the conventional regimen (oral metronidazole or 10 days of vancomycin) had fewer recurrences (8.6 versus 44.7% [p ≤ 0.01]; OR, 0.91; 95% CI, 0.028–0.294) and less attributable mortality (0% versus 7.1%; p = 0.058). We report an outbreak of CDI-027, mainly in patients with liver cirrhosis. Recurrence of CDI-027 was more common in those patients. A novel approach involving high-dose prolonged vancomycin taper as a first-line treatment, together with a bundle of outbreak measures, seemed to reduce the number of cases of CDI-027, recurrences, and attributable mortality. Nevertheless, this approach warrants further investigation.

Keywords

Vancomycin Clostridium Difficile Infection Rifaximin Fidaxomicin Oral Vancomycin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

We would like to thanks Thomas O’Boyle for his help in the preparation of the manuscript.

The preliminary results of this paper were presented at 26th European Congress of Clinical Microbiology and Infectious Diseases that was held in Amsterdam on April 2016.

Compliance with ethical standards

Funding

This work was partially supported by Fondo de Investigaciones Sanitarias (FIS), Research Project number PI13/00687, Carlos III Health Institute. Co-funded by the European Regional Development Fund (FEDER) “A way of making Europe”.

Conflicts of interests

The authors declare no conflicts of interest.

Ethical approval

This study was approved by the Ethics Committee of Hospital General Universitario Gregorio Marañón.

References

  1. 1.
    Ghose C (2013) Clostridium difficile infection in the twenty-first century. Emerg Microbes Infect 2(9):e62. doi: 10.1038/emi.2013.62 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Labbe AC, Poirier L, Maccannell D, Louie T, Savoie M, Beliveau C, Laverdiere M, Pepin J (2008) Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain. Antimicrob Agents Chemother 52(9):3180–3187. doi: 10.1128/AAC.00146-08
  3. 3.
    While A (2006) Lessons from Stoke Mandeville. Br J Community Nurs 11(9):406. doi: 10.12968/bjcn.2006.11.9.21764 CrossRefPubMedGoogle Scholar
  4. 4.
    Lopez-Urena D, Quesada-Gomez C, Miranda E, Fonseca M, Rodriguez-Cavallini E (2014) Spread of epidemic Clostridium difficile NAP1/027 in Latin America: case reports in Panama. J Med Microbiol 63(Pt 2):322–324. doi: 10.1099/jmm.0.066399-0 CrossRefPubMedGoogle Scholar
  5. 5.
    Oleastro M, Coelho M, Giao M, Coutinho S, Mota S, Santos A, Rodrigues J, Faria D (2014) Outbreak of Clostridium difficile PCR ribotype 027—the recent experience of a regional hospital. BMC Infect Dis 14:209. doi: 10.1186/1471-2334-14-209 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Marin M, Martin A, Alcolea A, Iglesias C, Alcala L, Pelaez T, Sanchez-Somolinos M, Bouza E (2014) [First case of autochthonous Clostridium difficile PCR ribotype 027 detected in Spain]. Enferm Infecc Microbiol Clin 32(6):355–358 [In Spanish]. doi: 10.1016/j.eimc.2013.07.004 CrossRefPubMedGoogle Scholar
  7. 7.
    Munoz-Velez M, Garcia-Bujalance S (2014) [Clostridium difficile infection due to ribotype 027: description of an imported case in Spain]. Enferm Infecc Microbiol Clin 32(8):542–543 [In Spanish]. doi: 10.1016/j.eimc.2013.10.009 CrossRefPubMedGoogle Scholar
  8. 8.
    Debast SB, Bauer MP, Kuijper EJ (2014) European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 20(Suppl 2):1–26. doi: 10.1111/1469-0691.12418
  9. 9.
    Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH (2010) Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 31(5):431–455. doi: 10.1086/651706
  10. 10.
    McFarland LV, Elmer GW, Surawicz CM (2002) Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 97(7):1769–1775. doi: 10.1111/j.1572-0241.2002.05839.x CrossRefPubMedGoogle Scholar
  11. 11.
    Tedesco FJ, Gordon D, Fortson WC (1985) Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. Am J Gastroenterol 80(11):867–868PubMedGoogle Scholar
  12. 12.
    Alcala L, Sanchez-Cambronero L, Catalan MP, Sanchez-Somolinos M, Pelaez MT, Marin M, Bouza E (2008) Comparison of three commercial methods for rapid detection of Clostridium difficile toxins a and B from fecal specimens. J Clin Microbiol 46(11):3833–3835. doi: 10.1128/JCM.01060-08 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Persson S, Torpdahl M, Olsen KE (2008) New multiplex PCR method for the detection of Clostridium difficile toxin a (tcdA) and toxin B (tcdB) and the binary toxin (cdtA/cdtB) genes applied to a Danish strain collection. Clin Microbiol Infect 14(11):1057–1064CrossRefPubMedGoogle Scholar
  14. 14.
    Lemee L, Dhalluin A, Testelin S, Mattrat MA, Maillard K, Lemeland JF, Pons JL (2004) Multiplex PCR targeting tpi (triose phosphate isomerase), tcdA (Toxin A), and tcdB (Toxin B) genes for toxigenic culture of Clostridium difficile. J Clin Microbiol 42(12):5710–5714CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Spigaglia P, Mastrantonio P (2002) Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC) among Clostridium difficile clinical isolates. J Clin Microbiol 40(9):3470–3475CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Stubbs SL, Brazier JS, O’Neill GL, Duerden BI (1999) PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. J Clin Microbiol 37(2):461–463PubMedPubMedCentralGoogle Scholar
  17. 17.
    van den Berg RJ, Schaap I, Templeton KE, Klaassen CH, Kuijper EJ (2007) Typing and subtyping of Clostridium difficile isolates by using multiple-locus variable-number tandem-repeat analysis. J Clin Microbiol 45(3):1024–1028. doi: 10.1128/JCM.02023-06 CrossRefPubMedGoogle Scholar
  18. 18.
    Alcala L, Reigadas E, Marin M, Martin A, Catalan P, Bouza E (2015) Impact of clinical awareness and diagnostic tests on the underdiagnosis of Clostridium difficile infection. Eur J Clin Microbiol Infect Dis. doi: 10.1007/s10096-015-2380-3 Google Scholar
  19. 19.
    McDonald LC, Killgore GE, Thompson A, Owens RC Jr, Kazakova SV, Sambol SP, Johnson S, Gerding DN (2005) An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 353(23):2433–2441. doi: 10.1056/NEJMoa051590 CrossRefPubMedGoogle Scholar
  20. 20.
    Wang P, Zhou Y, Wang Z, Xie S, Zhang T, Lin M, Li R, Tan J, Chen Y, Jiang B (2014) Identification of Clostridium difficile ribotype 027 for the first time in mainland China. Infect Control Hosp Epidemiol 35(1):95–98. doi: 10.1086/674405 CrossRefPubMedGoogle Scholar
  21. 21.
    Alcala L, Marin M, Martin A, Sanchez-Somolinos M, Catalan P, Pelaez MT, Bouza E (2011) Laboratory diagnosis of Clostridium difficile infection in Spain: a population-based survey. J Hosp Infect 79(1):13–17. doi: 10.1016/j.jhin.2011.05.017 CrossRefPubMedGoogle Scholar
  22. 22.
    Alcala L, Martin A, Marin M, Sanchez-Somolinos M, Catalan P, Pelaez T, Bouza E (2012) The undiagnosed cases of Clostridium difficile infection in a whole nation: where is the problem? Clin Microbiol Infect 18(7):E204–E213. doi: 10.1111/j.1469-0691.2012.03883.x CrossRefPubMedGoogle Scholar
  23. 23.
    Trifan A, Stoica O, Stanciu C, Cojocariu C, Singeap AM, Girleanu I, Miftode E (2015) Clostridium difficile infection in patients with liver disease: a review. Eur J Clin Microbiol Infect Dis. doi: 10.1007/s10096-015-2501-z PubMedGoogle Scholar
  24. 24.
    Vanjak D, Girault G, Branger C, Rufat P, Valla DC, Fantin B (2007) Risk factors for Clostridium difficile infection in a hepatology ward. Infect Control Hosp Epidemiol 28(2):202–204. doi: 10.1086/511790 CrossRefPubMedGoogle Scholar
  25. 25.
    Bajaj JS, Ananthakrishnan AN, Hafeezullah M, Zadvornova Y, Dye A, McGinley EL, Saeian K, Heuman D, Sanyal AJ, Hoffmann RG (2010) Clostridium difficile is associated with poor outcomes in patients with cirrhosis: a national and tertiary center perspective. Am J Gastroenterol 105(1):106–113. doi: 10.1038/ajg.2009.615 CrossRefPubMedGoogle Scholar
  26. 26.
    Mullen KD, Sanyal AJ, Bass NM, Poordad FF, Sheikh MY, Frederick RT, Bortey E, Forbes WP (2014) Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy. Clin Gastroenterol Hepatol 12(8):1390.e2–1397.e2. doi: 10.1016/j.cgh.2013.12.021 CrossRefGoogle Scholar
  27. 27.
    Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP (2010) Rifaximin treatment in hepatic encephalopathy. N Engl J Med 362(12):1071–1081. doi: 10.1056/NEJMoa0907893 CrossRefPubMedGoogle Scholar
  28. 28.
    Neff GW, Jones M, Jonas M, Ravinuthala R, Novick D, Kaiser TE, Kemmer N (2013) Lack of Clostridium difficile infection in patients treated with rifaximin for hepatic encephalopathy: a retrospective analysis. J Clin Gastroenterol 47(2):188–192. doi: 10.1097/MCG.0b013e318276be13 CrossRefPubMedGoogle Scholar
  29. 29.
    Mattila E, Arkkila P, Mattila PS, Tarkka E, Tissari P, Anttila VJ (2013) Rifaximin in the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther 37(1):122–128. doi: 10.1111/apt.12111 CrossRefPubMedGoogle Scholar
  30. 30.
    Patrick Basu P, Dinani A, Rayapudi K, Pacana T, Shah NJ, Hampole H, Krishnaswamy NV, Mohan V (2010) Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial. Therap Adv Gastroenterol 3(4):221–225. doi: 10.1177/1756283X10372985 CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Johnson S, Schriever C, Galang M, Kelly CP, Gerding DN (2007) Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 44(6):846–848. doi: 10.1086/511870 CrossRefPubMedGoogle Scholar
  32. 32.
    Carman RJ, Boone JH, Grover H, Wickham KN, Chen L (2012) In vivo selection of rifamycin-resistant Clostridium difficile during rifaximin therapy. Antimicrob Agents Chemother 56(11):6019–6020. doi: 10.1128/AAC.00974-12 CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Zullo A, Hassan C, Ridola L, Lorenzetti R, Campo SM, Riggio O (2012) Rifaximin therapy and hepatic encephalopathy: pros and cons. World J Gastrointest Pharmacol Ther 3(4):62–67. doi: 10.4292/wjgpt.v3.i4.62 CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Gerding DN, Muto CA, Owens RC Jr (2008) Treatment of Clostridium difficile infection. Clin Infect Dis 46(Suppl 1):S32–S42. doi: 10.1086/521860 CrossRefPubMedGoogle Scholar
  35. 35.
    Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK (2011) Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 364(5):422–431. doi: 10.1056/NEJMoa0910812 CrossRefPubMedGoogle Scholar
  36. 36.
    Cornely OA, Miller MA, Louie TJ, Crook DW, Gorbach SL (2012) Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis 55(Suppl 2):S154–S161. doi: 10.1093/cid/cis462 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  • E. Bouza
    • 1
    • 2
    • 3
    • 4
    Email author
  • L. Alcalá
    • 1
    • 3
  • M. Marín
    • 1
    • 2
    • 3
    • 4
  • M. Valerio
    • 1
    • 3
  • E. Reigadas
    • 1
    • 3
  • P. Muñoz
    • 1
    • 2
    • 3
    • 4
  • M. González-Del Vecchio
    • 1
    • 3
  • V. de Egea
    • 1
    • 3
    Email author
  1. 1.Clinical Microbiology and Infectious DiseasesHospital General Universitario Gregorio MarañónMadridSpain
  2. 2.Medicine Department, School of MedicineUniversidad Complutense de MadridMadridSpain
  3. 3.Instituto de Investigación Sanitaria Gregorio MarañónMadridSpain
  4. 4.CIBER Enfermedades Respiratorias-CIBERES (CB06/06/0058)MadridSpain

Personalised recommendations